Abstract |
The pharmacokinetics of a radiolabelled analog of helenalin, [3H]- plenolin ([3H]-11,13- dihydrohelenalin), was determined in BDF1 mice following intravenous, intraperitoneal, and oral administration. A two-compartment pharmacokinetic model predicted that the maximum terminal (beta) half-life of [3H]- plenolin was 57.3 hours. Urinary excretion accounted for 40.3% to 64.4% of the administered radioactivity, while fecal excretion accounted for 9.3% to 39.7%. The fecal excretion data also suggested that [3H]- plenolin was secreted in the bile. Following intraperitoneal administration of [3H]- plenolin, no radioactivity was sequestered in the major organs. However, radioactivity was sustained in the carcass and skin for 24 days. [3H]- Plenolin was rapidly taken up by murine tumor cells and human fibroblasts. The drug did not significantly associate with DNA, RNA, or protein of P388 leukemia or human fibroblast cells.
|
Authors | A A Grippo, S D Wyrick, K H Lee, R P Shrewsbury, I H Hall |
Journal | Planta medica
(Planta Med)
Vol. 57
Issue 4
Pg. 309-14
(Aug 1991)
ISSN: 0032-0943 [Print] Germany |
PMID | 1723209
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- DNA, Neoplasm
- Sesquiterpenes
- Serum Albumin, Bovine
- plenolin
- RNA
|
Topics |
- Animals
- Antineoplastic Agents, Phytogenic
(pharmacokinetics)
- DNA, Neoplasm
(metabolism)
- Humans
- Leukemia P388
(genetics, metabolism)
- Male
- Mice
- Molecular Structure
- RNA
(metabolism)
- Serum Albumin, Bovine
(metabolism)
- Sesquiterpenes
(pharmacokinetics)
- Tissue Distribution
|